StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology cash

Cash and short-term investments held at the end of each period.

Kura Oncology's cash was $492.10M at Sep 30, 2026. For fiscal 2025 it was $667.24M, down 8.3% from the year before. Over ten years it grew 45.7% a year on average. The highest annual figure on record is $727.40M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$667.24M-8.3%
FY2024Dec 31, 2024$727.40M+71.6%
FY2023Dec 31, 2023$423.96M-3.2%
FY2022Dec 31, 2022$437.99M-15.4%
FY2021Dec 31, 2021$517.96M-18.2%
FY2020Dec 31, 2020$633.32M+167.3%
FY2019Dec 31, 2019$236.89M+32.4%
FY2018Dec 31, 2018$178.99M+92.2%
FY2017Dec 31, 2017$93.15M+857.8%
FY2016Dec 31, 2016$9.73M-37.0%
FY2015Dec 31, 2015$15.44M+1273.9%
FY2014Dec 31, 2014$1.12M+17013.3%
FY2013Dec 31, 2013$6.57K+36.8%
FY2012Dec 31, 2012$4.80K+13.8%
FY2011Dec 31, 2011$4.22K-84.3%
FY2010Dec 31, 2010$26.90K+141.4%
FY2009Dec 31, 2009$11.14K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$492.10M-10.5%
Q2 FY2026Jun 30, 2026$519.03M-17.7%
Q1 FY2026Mar 31, 2026$580.82M-11.8%
Q4 FY2025Dec 31, 2025$667.24M-8.3%
Q3 FY2025Sep 30, 2025$549.67M+20.7%
Q2 FY2025Jun 30, 2025$630.73M+28.3%
Q1 FY2025Mar 31, 2025$658.19M+24.9%
Q4 FY2024Dec 31, 2024$727.40M+71.6%
Q3 FY2024Sep 30, 2024$455.30M+0.6%
Q2 FY2024Jun 30, 2024$491.52M+3.0%
Q1 FY2024Mar 31, 2024$527.12M+29.9%
Q4 FY2023Dec 31, 2023$423.96M-3.2%
Q3 FY2023Sep 30, 2023$452.59M+5.8%
Q2 FY2023Jun 30, 2023$476.98M+5.9%
Q1 FY2023Mar 31, 2023$405.90M-15.5%
Q4 FY2022Dec 31, 2022$437.99M-15.4%
Q3 FY2022Sep 30, 2022$427.78M-21.3%
Q2 FY2022Jun 30, 2022$450.26M-20.7%
Q1 FY2022Mar 31, 2022$480.08M-20.5%
Q4 FY2021Dec 31, 2021$517.96M-18.2%
Q3 FY2021Sep 30, 2021$543.45M+67.0%
Q2 FY2021Jun 30, 2021$567.49M+67.5%
Q1 FY2021Mar 31, 2021$603.87M+178.4%
Q4 FY2020Dec 31, 2020$633.32M+167.3%
Q3 FY2020Sep 30, 2020$325.41M+30.1%
Q2 FY2020Jun 30, 2020$338.87M+29.6%
Q1 FY2020Mar 31, 2020$216.94M+31.1%
Q4 FY2019Dec 31, 2019$236.89M+32.4%
Q3 FY2019Sep 30, 2019$250.13M+1116.1%
Q2 FY2019Jun 30, 2019$261.41M+1380.4%
Q1 FY2019Mar 31, 2019$165.53M+524.2%
Q4 FY2018Dec 31, 2018$178.99M+92.2%
Q3 FY2018Sep 30, 2018$20.57M-11.9%
Q2 FY2018Jun 30, 2018$17.66M+45.3%
Q1 FY2018Mar 31, 2018$26.52M+149.2%
Q4 FY2017Dec 31, 2017$93.15M+857.8%
Q3 FY2017Sep 30, 2017$23.34M–
Q2 FY2017Jun 30, 2017$12.15M–
Q1 FY2017Mar 31, 2017$10.64M–
Q4 FY2016Dec 31, 2016$9.73M–

More Kura Oncology figures

See a number that looks wrong?